Medullary thyroid cancer: targeting the RET kinase pathway with sorafenib/tipifarnib. Mol Cancer Ther 2008 May;7(5):1001-6
Date
05/01/2008Pubmed ID
18445656DOI
10.1158/1535-7163.MCT-07-2422Scopus ID
2-s2.0-49849083911 (requires institutional sign-in at Scopus site) 50 CitationsAbstract
Medullary thyroid carcinoma (MTC) is an uncommon malignancy of hereditary and sporadic presentation. Mutations in the RET proto-oncogene are involved in the pathogenesis of familial MTC and >50% of the sporadic cases. Currently, there is no effective treatment for recurrent or metastatic MTC. We report here a rapid response to a sorafenib (RET and RAF kinase and vascular endothelial growth factor receptor inhibitor)--based regimen in a patient with sporadic MTC who had advanced, progressive disease and a novel RET kinase aberration at exon 11 shown in tumor tissue.
Author List
Hong D, Ye L, Gagel R, Chintala L, El Naggar AK, Wright J, Kurzrock RAuthor
Razelle Kurzrock MD Center Associate Director, Professor in the Medicine department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdultAmino Acid Sequence
Antineoplastic Agents
Benzenesulfonates
Carcinoma, Medullary
Cell Line, Tumor
Exons
Humans
Male
Molecular Sequence Data
Niacinamide
Phenylurea Compounds
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-ret
Pyridines
Quinolones
Thyroid Neoplasms